pCDCAR1 CD19 h(28ζ), T(CAR-T-2-L332-2Z)
The vector of anti-CD19 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to a CD28 transmembrane domain/ endodomain and CD3-zeta signaling domains. And the vector product was designed for the treatment of chronic lymphoid leukemia.
Targeting Cell Type
Chronic lymphocytic leukemia (CLL)
Discription of Signaling Cassetes
CD28 (Cluster of Differentiation 28) is one of the proteins expressed on T cells that provide co-stimulatorysignals required for T cell activation and survival. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2) proteins which are expressed on antigen-presenting cells(APC). CD28 modulates the primary TCR/CD3ζ signal in a different fashion than the late costimulatory elements OX40 and 4-1BB. CD28 enhances the expression of downstream regulators that impact on T-cell proliferation, death, differentiation, and effector functions. CAR+ T cells containing the CD28 endodomain showed strikingly enhanced sustained T cell activation, growth, survival. And CD28 results in a brightly expressed, stable receptor as the transmembrane domain. Including CD28 costimulatory domains in CARs led to enhanced anti-malignancy efficacy.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta,which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CD19 scFv h(CD28-CD3ζ) CARNK, pCDCAR1
||Anti-CD19 (105974) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (104881) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (4G7) h(CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CD19 (Coltuximab) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (FMC-63) h(t2B4) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 105974) Viral Particle
||Anti-CD19 (S2) h(CD28-41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 scFv h(CD3ζ) CART, pCDCAR1
||Anti-CD19 (104876) h(41BB-CD3ζ) CAR, pCDCAR1
||Anti-CD19 (4G7) h(41BB-CD3ζ) Multi-chain CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD3ζ, FMC63) Viral Particle
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, 47G4) Viral Particle
||Lenti-CD19 CAR (scFv-CD3ζ-DAP10, SJ25C1) Viral Particle
||Anti-CD19 scFv h(FcεRIγ) CARNK, pCDCAR1
||Anti-CD19 scFv h(41BB-CD28-CD3ζ) CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD27-CD3ζ, 47G4) Viral Particle
||Lenti-CD19 CAR (scFv-CD28-FcεRIγ, FMC63) Viral Particle
||Lenti-CD19 CAR (scFv-CD28, FMC63) Viral Particle
||Anti-CD19 (105977) h(41BB-CD3ζ) CAR, pCDCAR1